

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

CT-2A

RRID:CVCL_ZJ44

Type: Cell Line

Proper Citation

RRID:CVCL_ZJ44

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_ZJ44

Proper Citation: RRID:CVCL_ZJ44

Description: Cell line CT-2A is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Sex unspecified

Disease: Mouse glioblastoma

Defining Citation: [PMID:1418222](#), [PMID:16911584](#), [PMID:17701911](#), [PMID:22514559](#)

Comments: Characteristics: Established from a tumor maintained through serial intracranial transplants., Characteristics: Mouse model for therapeutic research on brain malignancies (Millipore=SCC194).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: CT-2A

Synonyms: CT2A

Cross References: Millipore:SCC194, Wikidata:Q98125793

ID: CVCL_ZJ44

Record Creation Time: 20220427T215525+0000

Record Last Update: 20260801T235522+0000

Ratings and Alerts

No rating or validation information has been found for CT-2A.

No alerts have been found for CT-2A.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ahmad F, et al. (2026) Systemic cyst(e)inase administration induces ferroptosis and synergizes with temozolomide in glioblastoma. *iScience*, 29(1), 114350.

Rosi??ska S, et al. (2025) Junctional adhesion molecule C limits glioblastoma stem-like cell invasion by regulating integrin adhesion at the endothelial interface. *Cell reports*, 44(9), 116194.

Kim HC, et al. (2025) Gut microbiota dysbiosis induced by brain tumors modulates the efficacy of immunotherapy. *Cell reports*, 44(7), 115825.

Rashidi A, et al. (2024) Myeloid cell-derived creatine in the hypoxic niche promotes glioblastoma growth. *Cell metabolism*, 36(1), 62.

Zhong J, et al. (2024) Distinct roles of TREM2 in central nervous system cancers and peripheral cancers. *Cancer cell*, 42(6), 968.

Kim KS, et al. (2024) Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas. *Neuro-oncology*, 26(11), 2044.

Schweiger MW, et al. (2024) Glioblastoma extracellular vesicles modulate immune PD-L1 expression in accessory macrophages upon radiotherapy. *iScience*, 27(2), 108807.

Zhu R, et al. (2024) ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. *Cell metabolism*.

Tang M, et al. (2024) Inhibition of thioredoxin reductase 1 sensitizes glucose-starved glioblastoma cells to disulfidptosis. *Cell death and differentiation*.

Srinivasan ES, et al. (2023) Gold Nanostars Obviate Limitations to Laser Interstitial Thermal Therapy (LITT) for the Treatment of Intracranial Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(16), 3214.

Blomberg E, et al. (2023) Differential roles of type I interferon signaling in tumor versus host cells in experimental glioma models. *Translational oncology*, 28, 101607.

Iorgulescu JB, et al. (2023) Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model. *Frontiers in immunology*, 14, 1297932.

Noffsinger B, et al. (2021) Technical choices significantly alter the adaptive immune response against immunocompetent murine gliomas in a model-dependent manner. *Journal of neuro-oncology*, 154(2), 145.